IL295512A - Methods for treating tauopathy - Google Patents
Methods for treating tauopathyInfo
- Publication number
- IL295512A IL295512A IL295512A IL29551222A IL295512A IL 295512 A IL295512 A IL 295512A IL 295512 A IL295512 A IL 295512A IL 29551222 A IL29551222 A IL 29551222A IL 295512 A IL295512 A IL 295512A
- Authority
- IL
- Israel
- Prior art keywords
- deuterated
- optionally substituted
- ester
- acid
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976958P | 2020-02-14 | 2020-02-14 | |
| PCT/US2021/017981 WO2021163580A1 (en) | 2020-02-14 | 2021-02-12 | Methods for treating tauopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295512A true IL295512A (en) | 2022-10-01 |
Family
ID=77273602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295512A IL295512A (en) | 2020-02-14 | 2021-02-12 | Methods for treating tauopathy |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210251933A1 (https=) |
| EP (1) | EP4103169A4 (https=) |
| JP (2) | JP2023513901A (https=) |
| KR (1) | KR20220140808A (https=) |
| CN (1) | CN116507325A (https=) |
| AU (1) | AU2021220981A1 (https=) |
| CA (1) | CA3171330A1 (https=) |
| IL (1) | IL295512A (https=) |
| WO (1) | WO2021163580A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11510889B2 (en) | 2021-02-05 | 2022-11-29 | Retrotope, Inc. | Methods for inhibiting the progression of neurodegenerative diseases |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| WO2022170134A2 (en) * | 2021-02-05 | 2022-08-11 | Retrotope, Inc. | Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof |
| US11491130B2 (en) * | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
| KR20240055796A (ko) * | 2021-09-03 | 2024-04-29 | 바이오지바 엘엘씨 | 중수소화 pufa를 이용한 세포 기능장애 및 세포 사멸의 억제를 위한 방법, 시스템 및 조성물 |
| IL313592A (en) * | 2021-12-21 | 2024-08-01 | Biojiva Llc | Methods and preparations for the treatment of inflammatory disease |
| WO2023192406A2 (en) * | 2022-03-30 | 2023-10-05 | Retrotope, Inc. | Prophylactic methods for treating als |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10052299B2 (en) * | 2009-10-30 | 2018-08-21 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| JP6106157B2 (ja) * | 2011-04-26 | 2017-03-29 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | 神経変性障害および筋疾患に関与するｐｕｆａ |
| WO2012148930A2 (en) * | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Oxidative retinal diseases |
| CN110167546A (zh) * | 2016-11-17 | 2019-08-23 | 乐巢拓普有限公司 | 同位素修饰的组分及其治疗用途 |
| EP3461479B1 (en) * | 2017-09-27 | 2021-06-16 | Julie Blivet | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions |
| JP2021527648A (ja) * | 2018-06-15 | 2021-10-14 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の低減 |
-
2021
- 2021-02-12 CA CA3171330A patent/CA3171330A1/en active Pending
- 2021-02-12 AU AU2021220981A patent/AU2021220981A1/en active Pending
- 2021-02-12 US US17/175,397 patent/US20210251933A1/en not_active Abandoned
- 2021-02-12 WO PCT/US2021/017981 patent/WO2021163580A1/en not_active Ceased
- 2021-02-12 CN CN202180028457.1A patent/CN116507325A/zh active Pending
- 2021-02-12 KR KR1020227031617A patent/KR20220140808A/ko active Pending
- 2021-02-12 IL IL295512A patent/IL295512A/en unknown
- 2021-02-12 EP EP21753302.5A patent/EP4103169A4/en active Pending
- 2021-02-12 JP JP2022548978A patent/JP2023513901A/ja active Pending
-
2024
- 2024-07-09 US US18/767,538 patent/US20250177339A1/en active Pending
-
2025
- 2025-11-25 JP JP2025202414A patent/JP2026035680A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021163580A1 (en) | 2021-08-19 |
| US20250177339A1 (en) | 2025-06-05 |
| CN116507325A (zh) | 2023-07-28 |
| US20210251933A1 (en) | 2021-08-19 |
| JP2023513901A (ja) | 2023-04-04 |
| CA3171330A1 (en) | 2021-08-19 |
| JP2026035680A (ja) | 2026-03-04 |
| EP4103169A1 (en) | 2022-12-21 |
| AU2021220981A1 (en) | 2022-09-22 |
| KR20220140808A (ko) | 2022-10-18 |
| EP4103169A4 (en) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295512A (en) | Methods for treating tauopathy | |
| IL295459A (en) | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | |
| US20250215026A1 (en) | Deuterated Compounds, Compositions and Uses | |
| IL297849A (en) | The composition for use in the treatment of apol1-related disease | |
| JP2024096123A (ja) | 集団におけるジアミノフェノチアジンの最適化投与 | |
| US20240041847A1 (en) | Compounds and methods of treating retinal degeneration | |
| BR122019017719B1 (pt) | Inibidores de glicosilceramida sintase | |
| US11564924B2 (en) | Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound | |
| WO2011006157A2 (en) | Rxr agonist compounds and methods | |
| IL264765B1 (en) | Amide compounds, their pharmaceutical preparations and methods of using them | |
| US20070129439A1 (en) | Compositions containing substituted quinolines and substituted diphenyl sulfones and methods of use | |
| IL322463A (en) | Deuterated d-serine analogs and their uses | |
| ES2959243T3 (es) | Nuevo tratamiento de enfermedades mitocondriales | |
| IL295783A (en) | Processes for isotopic modification of polyunsaturated fatty acids and their derivatives | |
| US10022418B2 (en) | Compositions and methods for treating beta-amyloid related diseases | |
| DK2462131T3 (en) | Preparations and Methods for Treating Beta-Amyloid-Related Diseases | |
| IL303521A (en) | Masitinib for the treatment of alzheimer's disease | |
| WO2016130908A1 (en) | Therapeutic polysaccharide midi-gagr and related materials and methods | |
| IL321581A (en) | Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors | |
| WO2026044078A1 (en) | Compounds, compositions, and method of use to detect islet amyloid polypeptide (iapp) and inhibit iapp, alpha-synuclein and tau protein aggregation | |
| US20100305157A1 (en) | derivatives of dicarboxylic amino acids and their application in the treatment of neurodegenerative diseases | |
| WO2025131275A1 (en) | (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1 -yl)pyrimidin-5-yl)(imino)(methyl)-lamda6-sulfanone for use in the treatment of colitis, parkinson disease, tauopathy, als and alzheimer's disease | |
| Tan et al. | Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders | |
| Thiele | Parkinson's Disease: Prodrug Approaches for Improving the Delivery of Therapeutic Agents |